Zhang Bei, Barekati Zeinab, Kohler Corina, Radpour Ramin, Asadollahi Reza, Holzgreve Wolfgang, Zhong Xiao Yan
Department of Biomedicine, Women's Hospital, University of Basel, Basel, Switzerland.
Ann Clin Lab Sci. 2010 Summer;40(3):218-25.
Ovarian cancer remains a leading cause of death from gynecological malignancy. Early diagnosis is the most important determinant of survival. Current diagnostic tools have had very limited success in early detection. In recent years, the advancing techniques for proteomics have accelerated the discovery of ovarian cancer biomarkers. Numerous proteomics-based molecular biomarkers/panels have been identified and hold great potential for diagnostic applications, but they need further development and validation. This article reviews recently published data on the diagnosis of ovarian cancer with proteomics, including the major proteomics technologies and promising strategies for biomarker discovery and development.
卵巢癌仍然是妇科恶性肿瘤死亡的主要原因。早期诊断是生存的最重要决定因素。目前的诊断工具在早期检测方面取得的成功非常有限。近年来,蛋白质组学技术的进步加速了卵巢癌生物标志物的发现。已经鉴定出许多基于蛋白质组学的分子生物标志物/组合,在诊断应用方面具有巨大潜力,但它们需要进一步开发和验证。本文综述了最近发表的关于蛋白质组学诊断卵巢癌的数据,包括主要的蛋白质组学技术以及生物标志物发现和开发的有前景的策略。